Table 2.

Drug resistance mutations detected in screening samples.

		Mutations∗
Sample	Subtype†	Protease	NRTI	NNRTI	Integrase
5.ph17	CRF01_AE	None	None	V90I
6.ph17	CRF01_AE	L10F; L10V	None	E138G
10.ph17	B	L10V	None	none
11.ph17	CRF01_AE	M46L	None	none
17.ph17	CRF01_AE	None	D67N; K70R; M184V; T215F; T215I; T215S	A98G, G190A
21.ph17	B	M46L; A71V	None	K101Q;E138K
27.ph17	CRF01_AE	None	None	E138A
28.ph17	CRF01_AE	None	None	V106I	none
39.ph17	CRF01_AE	None	K65R; K70T; L74I; M184I	V90I; K103N; V108I; Y181C; M230L
2.ph18∗	B	L10I	None	V179D
17.ph18	B	L10V	None	none
18.ph18	CRF01_AE	None	None	V90I, V106I, E138G
32.ph18∗	CRF01_AE	None	Y115F; T215Y	Y188C; G190V
34.ph18	B	A71V; L90M	None	Y181C, H221Y
1.ph19	CRF01_AE	None	None	V106I

^∗Mutations associated with protease, reverse transcriptase (nucleoside – NRTI and non-nucleoside – NNRTI) and integrase inhibitors.

^†Subtype listed in the Stanford HIV Drug Resistance designation for Protease-RT FASTA submitted for that sample.

Bolded = treatment experienced, failing ART.

∗ Partners w/ another patient in the cohort.